You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Vaccine Portfolio

Demands for vaccines continues to increase as the world's population grows and changes. To meet this demand, GSK must deliver reliable, high quality vaccines and push the boundaries of science and technology to develop innovative vaccines.

 

Synflorix

Synflorix

Synflorix is a Pneumococcal polysaccharide conjugate vaccine. Indicated for Active immunization against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactivate serotype 19A in infants , and children from 6 weeks up to 5 years of age.

Read More

 

Synflorix

Rotarix

Rotarix is a live attenuated rotavirus vaccine Rotarix is indicated for the prevention of gastro-enteritis caused by rotavirus.

Read More

 

Synflorix

Havrix (720 Junior)

Havrix Adult is indicated for active immunization against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV, for Children and adolescents from 1 year up to and including 18 years of age.

Read More

 

Synflorix

Varilrix

Varilrix is indicated for active immunization against varicella of healthy subjects from the age of 12 months onwards.

Read More

 

Synflorix

Twinrix

Twinrix Adult is indicated for use in non-immune adults and adolescents of 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.

Read More

 

Synflorix

Havrix (1440 Adult)

Havrix Adult is indicated for active immunization against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV, from age 19 years and onwards.

Read More

 

Synflorix

Priorix

Priorix is indicated for the active immunization against measles, mumps and rubella.

Read More

 

Synflorix

Hiberix

Hiberix is indicated for active immunization of all infants from the age of 6 weeks against disease caused by Haemophilus influenzae type b.

Read More

 

Synflorix

Cervarix

Cervarix is indicated from the age of 9 years for the prevention of persistent infection, premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical, vulvar, vaginal and anal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV).

Read More

 

Trademarks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.